The lupus nephritis market is poised for significant growth over the coming years, driven by increasing disease awareness, improved diagnosis, and the expanding adoption of targeted therapies. The treatment landscape is evolving beyond conventional broad-spectrum immunosuppressants, with approved therapies such as belimumab, voclosporin, and obinutuzumab expanding treatment options for patients with active disease. At the same time, a robust pipeline of therapies such as Anifrolumab (SAPHNELO; AstraZeneca), Ianalumab (VAY736; Novartis/MorphoSys), Cenerimod (Idorsia Pharmaceuticals/Viatris), Rapcabtagene autoleucel (YTB323; Novartis), and others is expected to further transform disease management.
The lupus nephritis market is poised for significant growth over the coming years, driven by increasing disease awareness, improved diagnosis, and the expanding adoption of targeted therapies. The treatment landscape is evolving beyond conventional broad-spectrum immunosuppressants, with approved therapies such as belimumab, voclosporin, and obinutuzumab expanding treatment options for patients with active disease. At the same time, a robust pipeline of therapies such as Anifrolumab (SAPHNELO; AstraZeneca), Ianalumab (VAY736; Novartis/MorphoSys), Cenerimod (Idorsia Pharmaceuticals/Viatris), Rapcabtagene autoleucel (YTB323; Novartis), and others is expected to further transform disease management.